Restricted accessResearch articleFirst published online 2020-07
IL-10 Polymorphisms and Haplotypes Predict Susceptibility to Hepatocellular Carcinoma Occurrence in Patients with Hepatitis C Virus Infection from Northeast India
Chronic hepatitis C virus (HCV) infection leads to variable outcomes, ranging from prolonged slow hepatic damage leading to cirrhosis, and hepatocellular carcinoma (HCC). Polymorphism in cytokines IL-10 and IL-12 that impact the immune response to HCV infection may play a role in determining this outcome. This study was aimed to determine if polymorphisms in IL-10 and IL-12B contribute to HCV susceptibility and the risk of developing HCC in patients from Northeast India. IL-10 − 1082, −819, −592 polymorphisms and IL-12B −1188 polymorphisms were genotyped by polymerase chain reaction–restriction fragment length polymorphism in a total of 266 HCV-infected patients and 100 age- and sex-matched controls. In the HCV-infected subjects, 110 patients had chronic hepatitis C (CHC), 96 with liver cirrhosis, and 60 with HCC. Serum levels of IL-10 were also measured and correlated with disease severity. Haplotype analysis for IL-10 polymorphisms was carried out. Statistical data were analyzed using SPSS ver. 22.0. The frequency of IL-10 − 592 AA genotype/A allele was significantly higher in HCC patients than in CHC patients. The intermediate IL-10-producing ACC haplotype was significantly more frequent in HCC and cirrhotic patients than in CHC patients. No significant association was found for IL-10 − 819, −592 and IL-12B −1188 polymorphisms with the susceptibility to HCV infection or occurrence of HCC in HCV-infected patients. IL-10 − 592 CA polymorphism and IL-10 ACC haplotype are significant biomarkers of HCC in HCV-infected patients from Northeast India. Higher serum levels of IL-10 were also linked to higher disease severity.
Get full access to this article
View all access options for this article.
References
1.
AborsangayaKB, DembinskiI, KhatkarS, et al.Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology, 2007; 45:623–630.
2.
AcharyaSK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol, 2014; 4(Suppl 3):S27–S33.
3.
AfzalMS, TahirS, SalmanA, et al.Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries, 2011; 5:473–479.
4.
AkdisM, AabA, AltunbulakliC, et al.Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol, 2016; 138:984–1010.
5.
ArouchaDC, do CarmoRF, MouraP, et al.High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine, 2013; 62:421–425.
6.
AxleyP, AhmedZ, RaviS, et al.Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol, 2018; 6:79–84.
7.
BahgatNA, KamalMM, AbdelazizAO, et al.Interferon-γ and interleukin-10 gene polymorphisms are not predictors of chronic hepatitis C (genotype-4) disease progression. Asian Pac J Cancer Prev, 2015; 16:5025–5030.
8.
BarrettS, CollinsM, KennyC, et al.Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003; 71:212–218.
9.
BeiCH, BaiH, YuHP, et al.Combined effects of six cytokine gene polymorphisms and SNP-SNP interactions on hepatocellular carcinoma risk in Southern Guangxi, China. Asian Pac J Cancer Prev, 2014; 15:6961–6967.
10.
ChenH, ChengS, WangJ, et al.Interleukin-12B rs3212227 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep, 2012; 39:10235–10242.
11.
ChoobinH, BamdadT, and ShekarabiM. The pattern of antiviral protein expression induced by interferon λ1 in peripheral blood mononuclear cells of patients with chronic hepatitis C virus infection. Arch Virol, 2020; 165:583–592.
12.
ChuangJY, YangSS, LuYT, et al.IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis, 2009; 41:424–430.
13.
da SilvaNM, GermanoFN, Vidales-BrazBM, et al.Polymorphisms of IL-10 gene in patients infected with HCV under antiviral treatment in southern Brazil. Cytokine, 2015; 73:253–257.
14.
DingQ, ShiY, FanB, et al.The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls. PLoS One, 2013; 8:e57246.
15.
DondetiMF, El-MaadawyEA, and TalaatRM. Hepatitis-related hepatocellular carcinoma: insights into cytokine gene polymorphisms. World J Gastroenterol, 2016; 22:6800–6816.
16.
Edwards-SmithCJ, JonssonJR, PurdieDM, et al.Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology, 1999; 30:526–530.
17.
ElsayedHM, NabielY, and ShetaT. IL12 gene polymorphism in association with hepatocellular carcinoma in HCV-infected Egyptian patients. Immunol Invest, 2017; 46:123–133.
18.
ElwanN, AmrK, ElyamanyS, et al.Association of IL-12 B gene polymorphism with staging of liver disease in chronic HCV patients. Infect Disord Drug Targets, 2018; 18:122–128.
19.
GaoOJ, LiuDW, ZhangSY, et al.Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol, 2009; 15:5610–5619.
20.
HelalSF, GomaaHE, ThabetEH, et al.Impact of IL-10 (-1082)promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol, 2014; 7:19–24.
21.
HoshidaY, FuchsBC, BardeesyN, et al.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol, 2014; 61(1Suppl):S79–S90.
22.
HouldsworthA, MetznerM, RossolS, et al.Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res, 2005; 25:271–276.
23.
IrshadM, GuptaP, and IrshadK. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol, 2017; 9:1305–1314.
24.
KusumotoK, UtoH, HayashiK, et al.Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine, 2006; 34:24–31.
25.
LingalaS, and GhanyMG. Natural history of hepatitis C. Gastroenterol Clin North Am, 2015; 44:717–734.
26.
LuYL, WuX, HuangHL, et al.Allele polymorphisms of interleukin-10 and hepatitis B, C virus infection. Chin Med J, 2010; 123:1338–1344.
27.
MohammedMA, OmarNM, MohammedSA, et al.The significance of vitamin D receptor gene polymorphisms for susceptibility to hepatocellular carcinoma in subjects infected with hepatitis C virus. Gastroenterol Hepatol Open Access, 2017; 7:00246.
28.
MoreiraST, SilvaGF, de MoraesCF, et al.Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C. Meta Gene, 2016; 9:90–96.
29.
NaeemiH, AslamR, RazaSM, et al.Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol, 2018; 163:997–1008.
30.
NaslednikovaIO, KonenkovVI, RyazantsevaNV, et al.Role of genetically determined production of immunoregulatory cytokines in immunopathogenesis of chronic viral hepatitides. Bull Exp Biol Med, 2007; 143:706–712.
31.
OleksykTK, ThioCL, TrueloveAL, et al.Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun, 2005; 6:347–357.
32.
PaladinoN, FainboimH, TheilerG, et al.Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol, 2006; 80:9144–9150.
33.
PengQ, LiS, LaoX, et al.Interleukin-12B+1188A/C polymorphism contributes to increased hepatocellular carcinoma susceptibility: evidence from ameta-analysis. Clin Res Hepatol Gastroenterol, 2014; 38:735–743.
34.
PowellEE, Edwards-SmithCJ, HayJL, et al.Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000; 31:828–833.
35.
PuriP, AnandAC, SaraswatVA, et al.Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol, 2014; 4:106–116.
36.
RuzicM, PellicanoR, FabriM, et al.Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med, 2018; 60:185–191.
37.
SaxenaR, ChawlaYK, VermaI, et al.Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res, 2014; 34:117–128.
38.
SeegersD, ZwiersA, StroberW, et al.A TaqI polymorphism in the 3′UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun, 2002; 3:419–423.
39.
SepahiS, PasdarA, AhadiM, et al.Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case control study. Viral Immunol, 2014; 27:398–403.
40.
ShinHD, ParkBL, KimLH, et al.Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet, 2003; 12:901–906.
41.
SilvaOB, CorreiaNAA, de BarrosFT, et al.3’ untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin's lymphoma in Brazilian children and adolescents. Tumour Biol, 2019; 41:1010428319860400.
42.
SwiatekBJ. Is interleukin-10 gene polymorphism a predictive marker in HCV infection?. Cytokine Growth Factor Rev, 2012; 23:47–59.
43.
Swiatek-KoscielnaB, KaluznaE, StraussE, et al.Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: analysis of association with severity of disease and treatment outcome. Hum Immunol, 2017; 78:192–200.
44.
TanA, GaoY, YaoZ, et al.Genetic variants in IL12 influence both hepatitis B virus clearance and HBV-related hepatocellular carcinoma development in a Chinese male population. Tumour Biol, 2016; 37:6343–6348.
45.
TsengLH, LinMT, ShauWY, et al.Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens, 2006; 67:127–133.
46.
VidigalPG, GermerJJ, and ZeinNN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002; 36:271–277.
47.
WeiYG, LiuF, LiB, et al.Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol, 2011; 17:3941–3947.
48.
WestbrookRH, and DusheikoG. Natural history of hepatitis C. J Hepatol, 2014; 61(1Suppl):S58–S68.
49.
YanZ, and WangY. Viral and host factors associated with outcomes of hepatitis C virus infection (Review). Mol Med Rep, 2017; 15:2909–2924.
50.
YangR, GaoN, ChangQ, et al.The role of IDO, IL-10, and TGF-β in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol, 2019; 91:265–271.
51.
YangY, LuoC, FengR, et al.The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 2011; 137:947–952.
52.
YinLM, ZhuWF, WeiL, et al.Association of interleukin-12 p40 gene 3′-untranslated region polymorphism and outcome of HCV infection. World J Gastroenterol, 2004; 10:2330–2333.
53.
YoussefSS, Mostafa Abd El-AalA, SaadA, et al.Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients. Dis Markers, 2013; 35:431–437.
54.
ZhangS, WangY, LiuC, et al.Polymorphisms in the interleukin-10 gene and hepatocellular carcinoma: an updated meta-analysis of 12 case-control studies. Int J Clin Exp Med, 2016; 9:17140–17152.
55.
ZhouL, YaoF, LuanH, et al.Functional polymorphisms in the interleukin-12 gene contribute to cancer risk: evidence from a meta-analysis of 18 case-control studies. Gene, 2012; 510:71–77.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
